- Home
- FFA vs CYRX Comparison
FFA vs CYRX Comparison
Compare FFA & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- CYRX
- Stock Information
- Founded
- FFA 2004
- CYRX 1999
- Country
- FFA United States
- CYRX United States
- Employees
- FFA N/A
- CYRX N/A
- Industry
- FFA Investment Managers
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- CYRX Health Care
- Exchange
- FFA Nasdaq
- CYRX Nasdaq
- Market Cap
- FFA 416.1M
- CYRX 438.7M
- IPO Year
- FFA N/A
- CYRX N/A
- Fundamental
- Price
- FFA $21.41
- CYRX $9.44
- Analyst Decision
- FFA
- CYRX Strong Buy
- Analyst Count
- FFA 0
- CYRX 9
- Target Price
- FFA N/A
- CYRX $12.83
- AVG Volume (30 Days)
- FFA 26.1K
- CYRX 738.4K
- Earning Date
- FFA 01-01-0001
- CYRX 11-04-2025
- Dividend Yield
- FFA 6.72%
- CYRX N/A
- EPS Growth
- FFA N/A
- CYRX N/A
- EPS
- FFA N/A
- CYRX 1.27
- Revenue
- FFA N/A
- CYRX $243,795,000.00
- Revenue This Year
- FFA N/A
- CYRX N/A
- Revenue Next Year
- FFA N/A
- CYRX $9.20
- P/E Ratio
- FFA N/A
- CYRX $7.45
- Revenue Growth
- FFA N/A
- CYRX 41.27
- 52 Week Low
- FFA $15.84
- CYRX $4.58
- 52 Week High
- FFA $19.30
- CYRX $11.44
- Technical
- Relative Strength Index (RSI)
- FFA 49.35
- CYRX 55.42
- Support Level
- FFA $20.85
- CYRX $8.15
- Resistance Level
- FFA $21.54
- CYRX $9.29
- Average True Range (ATR)
- FFA 0.31
- CYRX 0.51
- MACD
- FFA -0.06
- CYRX 0.05
- Stochastic Oscillator
- FFA 55.39
- CYRX 89.67
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.